

# NAMEN ZDRAVLJENJA

Zdravstveni delavci (psihiater, psiholog, medicinska sestra ali socialni delavec) bodo v sodelovanju z bolnikom in njegovimi svojci postavili kratkoročne in dolgoročne cilje.



Nekaj primerov terapevtskih ciljev lahko preberete tu:<sup>1,2,9</sup>

- obvladovanje oz. zmanjševanje simptomov in njihovega negativnega vpliva na življenje z namenom doseganja želene stopnje funkcioniranja,
- preprečevanje ponovitve bolezni,
- preprečevanje hospitalizacij,
- preprečevanje ali lajšanje možnih neželenih učinkov zdravljenja,
- Vrnitev k vsakodnevnim dejavnostim (npr. delo, študij, samostojno življenje, druženje).

## Literatura

1. APA Clinical Guidelines. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2004.
2. Falkai P et al. *World J Biol Psychiatry* 2005; 6: 132–191.
3. Kendler KS et al. *Arch Gen Psychiatry* 1996; 53: 1022–1031.
4. World Health Organization. *The World Health Report: 2001: Mental health: new understanding, new hope.*
5. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision (DSM-IV-TR).* Arlington: American Psychiatric Publishing Inc. 2000.
6. Lieberman JA et al. *J Clin Psychiatry* 1996; 57 (suppl 9): 5–9.
7. Breier A et al. *Am J Psychiatry* 1994; 151: 20–26.
8. Robinson DG et al. *Am J Psychiatry* 1999; 156: 544–549.
9. National Institute for Clinical Excellence. *National Clinical Practice Guidelines Number 82.*
10. Howard R et al. *Am J Psychiatry* 2000; 157: 172–178.
11. Angermeyer MC et al. *Schizophr Bull* 1990; 16: 293–307.
12. Murray RM and Fearon P. *J Psychiatr Res* 1999; 33: 497–499.
13. Lang UE et al. *Cell Physiol Biochem* 2007; 20: 687–702.
14. Harrigan SM et al. *Psychol Med* 2003; 33: 97–110.
15. Bottlender R et al. *Schizophr Res* 2003; 62: 37–44.
16. Emsley R et al. *Curr Opin Psychiatry* 2008; 21: 173–177.
17. Awad AG et al. *Pharmacoeconomics* 2008; 26: 149–162.
18. Keith SJ et al. *Psychiatr Serv* 2004; 55: 997–1005.
19. Lieberman JA et al. *Pharmacol Rev* 2008; 60: 358–403.
20. Tandon R et al. *Psychoneuroendocrinology* 2003; 28 (suppl 1): 9–26.
21. Wyatt RJ. *Schizophr Bull* 1991; 17: 325–351.
22. Robinson DG et al. *Arch Gen Psychiatry* 1999; 56: 241–247.
23. Weiden PJ et al. *Psychiatr Serv* 2004; 55: 886–891.
24. Koen L et al. *Psychosomatics* 2007; 48: 128–134.
25. Novick D et al. *Psychiatry Res* 2010; 176: 109–113.
26. Kozma CM et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. *Current Medical*

Research and Opinion. 2011.27; 1603–1611.

PSY-SLO-018-180419 EM-09762